logo-loader
viewVolitionRx

VolitionRx Limited colorectal cancer screening on its way

Cancer diagnostics group Volition RX Limited (NYSEMKT:VRNX) expects to receive European Union CE Marking on its Nu. Q colorectal cancer blood test later this year, paving the way for a product launch in 2017.
Chief executive Cameron Reynolds explains why the company chose colorectal cancer screening as its first product from its Nu. Q platform and why it is initially targeting Europe. The US remains in its sights, and it also plans screening kits for other forms of cancer.

Quick facts: VolitionRx

Price: 4.65 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $191.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

2 days, 5 hours ago

2 min read